Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Clinical trial NCT00790036 · COMPLETED
Trial details
- NCT number
- NCT00790036
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-07-24
- Primary completion
- 2016-06-15
- Enrollment
- 742
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.